Veracyte to Present Over 10 Afirma-Focused Studies at 2025 American Thyroid Association Annual Meeting

Reuters

Sep 09

Veracyte to Present Over 10 Afirma-Focused Studies at 2025 American Thyroid Association Annual Meeting

Veracyte Inc., a leading cancer diagnostics company, has announced the presentation of 12 Afirma-related abstracts at the upcoming 2025 American Thyroid Association Annual Meeting. Scheduled from September 10-14 at the Westin Kierland in Scottsdale, Arizona, these studies highlight Veracyte's extensive work in thyroid cancer research, utilizing their Afirma Genomic Resource for Intelligent Discovery $(GRID)$. This resource is noted as the largest molecular database for thyroid nodules. The abstracts, which will be presented in the future at the meeting, cover a range of topics including potential prognostic and therapeutic markers in thyroid tumors, preoperative thyroid nodule mRNA expression signatures, and molecular profiling of patients with indeterminate thyroid nodules. The studies aim to advance scientific understanding and inform innovations in patient care within the field of thyroid cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veracyte Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250909813969) on September 09, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2566695690"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2566695690\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2566695690?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-09 21:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2566695690","market":"fut","top_or_hot":-1,"title":"Veracyte to Present Over 10 Afirma-Focused Studies at 2025 American Thyroid Association Annual Meeting","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Veracyte to Present Over 10 Afirma-Focused Studies at 2025 American Thyroid Association Annual Meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/VCYT\">Veracyte Inc</a>., a leading cancer diagnostics company, has announced the presentation of 12 Afirma-related abstracts at the upcoming 2025 American Thyroid Association Annual Meeting. Scheduled from September 10-14 at the Westin Kierland in Scottsdale, Arizona, these studies highlight Veracyte's extensive work in thyroid cancer research, utilizing their Afirma Genomic Resource for Intelligent Discovery <a href=\"https://laohu8.com/S/GRID\">$(GRID)$</a>. This resource is noted as the largest molecular database for thyroid nodules. The abstracts, which will be presented in the future at the meeting, cover a range of topics including potential prognostic and therapeutic markers in thyroid tumors, preoperative thyroid nodule mRNA expression signatures, and molecular profiling of patients with indeterminate thyroid nodules. The studies aim to advance scientific understanding and inform innovations in patient care within the field of thyroid cancer.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veracyte Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250909813969) on September 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Veracyte to Present Over 10 Afirma-Focused Studies at 2025 American Thyroid Association Annual Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVeracyte to Present Over 10 Afirma-Focused Studies at 2025 American Thyroid Association Annual Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-09 21:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Veracyte to Present Over 10 Afirma-Focused Studies at 2025 American Thyroid Association Annual Meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/VCYT\">Veracyte Inc</a>., a leading cancer diagnostics company, has announced the presentation of 12 Afirma-related abstracts at the upcoming 2025 American Thyroid Association Annual Meeting. Scheduled from September 10-14 at the Westin Kierland in Scottsdale, Arizona, these studies highlight Veracyte's extensive work in thyroid cancer research, utilizing their Afirma Genomic Resource for Intelligent Discovery <a href=\"https://laohu8.com/S/GRID\">$(GRID)$</a>. This resource is noted as the largest molecular database for thyroid nodules. The abstracts, which will be presented in the future at the meeting, cover a range of topics including potential prognostic and therapeutic markers in thyroid tumors, preoperative thyroid nodule mRNA expression signatures, and molecular profiling of patients with indeterminate thyroid nodules. The studies aim to advance scientific understanding and inform innovations in patient care within the field of thyroid cancer.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veracyte Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250909813969) on September 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250909:nNDL57DJP8:1","article_id":"2566695690","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2566695690","pubTimestamp":1757422912,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Veracyte Inc., a leading cancer diagnostics company, has announced the presentation of 12 Afirma-related abstracts at the upcoming 2025 American Thyroid Association Annual Meeting. Scheduled from September 10-14 at the Westin Kierland in Scottsdale, Arizona, these studies highlight Veracyte's extensive work in thyroid cancer research, utilizing their Afirma Genomic Resource for Intelligent Discovery . This resource is noted as the largest molecular database for thyroid nodules. The abstracts, which will be presented in the future at the meeting, cover a range of topics including potential prognostic and therapeutic markers in thyroid tumors, preoperative thyroid nodule mRNA expression signatures, and molecular profiling of patients with indeterminate thyroid nodules. The studies aim to advance scientific understanding and inform innovations in patient care within the field of thyroid cancer.Disclaimer: This news brief was created by Public Technologies  using generative artificial inte","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","VCYT":"Veracyte Inc"},"translate_title":"Veracyte将在2025年美国甲状腺协会年会上展示10多项以Afirma为重点的研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VCYT":0.9},"content_text":"Veracyte to Present Over 10 Afirma-Focused Studies at 2025 American Thyroid Association Annual Meeting\n    \n\nVeracyte Inc., a leading cancer diagnostics company, has announced the presentation of 12 Afirma-related abstracts at the upcoming 2025 American Thyroid Association Annual Meeting. Scheduled from September 10-14 at the Westin Kierland in Scottsdale, Arizona, these studies highlight Veracyte's extensive work in thyroid cancer research, utilizing their Afirma Genomic Resource for Intelligent Discovery $(GRID)$. This resource is noted as the largest molecular database for thyroid nodules. The abstracts, which will be presented in the future at the meeting, cover a range of topics including potential prognostic and therapeutic markers in thyroid tumors, preoperative thyroid nodule mRNA expression signatures, and molecular profiling of patients with indeterminate thyroid nodules. The studies aim to advance scientific understanding and inform innovations in patient care within the field of thyroid cancer.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veracyte Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250909813969) on September 09, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}